Douglas Magno Guimaraes

Dr. Douglas Magno Guimaraes

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2016 in Oncotarget
Verified
Journal Article
Open access
CMCamila S. Matsumoto
Camila S. Matsumoto
LALuciana Oliveira de Almeida
Luciana Oliveira de Almeida
DGDouglas Magno Guimaraes
Douglas Magno Guimaraes
MMManoela D. Martins
Manoela D. Martins
PPPetros Papagerakis
Petros Papagerakis
CSCristiane H Squarize
Cristiane H Squarize
PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells

1 May 2017 in Stem Cell Research
Verified
Journal Article
Open access
LALuciana Oliveira de Almeida
Luciana Oliveira de Almeida
DGDouglas Magno Guimaraes
Douglas Magno Guimaraes
MMManoela D. Martins
Manoela D. Martins
MMMarco A.T. Martins
Marco A.T. Martins
KWKristy A. Warner
Kristy A. Warner
CSCristiane H Squarize
Cristiane H Squarize
Adenoid cystic carcinoma (ACC) is an uncommon malignancy of the salivary glands that is characterized by local recurrence and distant metastasis due to its resistance to conventional therapy. Platinum-based therapies have been extensively explored as a treatment for ACC, but they show little effectiveness. Studies have shown that a specific group of tumor cells, harboring characteristics of cancer stem cells (CSCs), are involved in chemoresistance of myeloid leukemias, breast, colorectal and pancreatic carcinomas. Therapeutic strategies that target CSCs improve the survival of patients by decreasing the rates of tumor relapse, and epigenetic drugs, such as histone deacetylase inhibitors (HDACi), have shown promising results in targeting CSCs. In this study, we investigated the effect of the HDACi Suberoylanilide hydroxamic acid (Vorinostat), and cisplatin, alone or in combination, on CSCs and non-CSCs from ACC. We used CSCs as a biological marker for tumor resistance to therapy in patient-derived xenograft (PDX) samples and ACC primary cells. We found that cisplatin reduced tumor viability, but enriched the population of CSCs. Systemic administration of Vorinostat reduced the number of detectable CSCs in vivo and in vitro, and a low dose of Vorinostat decreased tumor cell viability. However, the combination of Vorinostat and cisplatin was extremely effective in depleting CSCs and reducing tumor viability in all ACC primary cells by activating cellular senescence. These observations suggest that HDACi and intercalating agents act more efficiently in combination to destroy tumor cells and their stem cells.

7 June 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
DGDouglas Magno Guimaraes
Douglas Magno Guimaraes
LALuciana Oliveira de Almeida
Luciana Oliveira de Almeida
MMManoela D. Martins
Manoela D. Martins
KWKristy A. Warner
Kristy A. Warner
Alan Roger Santos-SilvaAlan Roger Santos-Silva
Alan Roger Santos-Silva
RCRogerio Castilho
Rogerio Castilho
Sensitizing mucoepidermoid carcinomas to chemotherapy by targeted disruption of cancer stem cells

1 January 2018 in Journal of Cranio-Maxillofacial Surgery
Verified
Journal Article
Closed access
LSLucas Lacerda de Souza
Lucas Lacerda de Souza
FPFlavia Sirotheau Correa Pontes
Flavia Sirotheau Correa Pontes
HPHelder Antonio Rebelo Pontes
Helder Antonio Rebelo Pontes
NNNicolau Conte Neto
Nicolau Conte Neto
WCWaldner Ricardo Souza de Carvalho
Waldner Ricardo Souza de Carvalho
DGDouglas Magno Guimaraes
Douglas Magno Guimaraes

4 January 2016 in Cancers
Verified
Journal Article
Open access
PDF file
LALuciana Oliveira de Almeida
Luciana Oliveira de Almeida
DGDouglas Magno Guimaraes
Douglas Magno Guimaraes
CSCristiane H Squarize
Cristiane H Squarize
RCRogerio Castilho
Rogerio Castilho
Cancer stem cells (CSCs) are a subpopulation of tumor cells endowed with self-renewal properties and the capacity to dynamically adapt to physiological changes that occur in the tumor microenvironment. CSCs play a central role in resistance to therapy and long-term disease recurrence. Better characterization and understanding of the available in vitro tools to study the biology of CSCs will improve our knowledge of the processes underlying tumor response to therapy, and will help in the screening and development of novel strategies targeting CSCs. We investigated the behavior of different populations of head and neck CSCs grown under ultra-low adhesion conditions. We found that invasion and adhesion differ among tumorsphere subtypes (holospheres, merospheres and paraspheres), and their tumor cell progeny also harbor distinct self-renewal and clonogenic potentials. Furthermore, holospheres contained higher numbers of head and neck CSCs, as detected by the CD44 cancer stem cell marker and aldehyde dehydrogenase (ALDH) enzymatic activity. In addition, holospheres showed reduced proliferation (Ki67), hypoacetylation of histones, and increased expression of the BMI-1 epithelial stem cell marker, suggesting activation of stem cell programs. Collectively, our results suggest that holospheres enrich a specific population of CSCs with enhanced “stemness” and invasive potential.

19 September 2018 in Lasers in Medical Science
Verified
Journal Article
Closed access
PDF file
TSTatiana Dias Schalch
Tatiana Dias Schalch
MFMaria Helena V Fernandes
Maria Helena V Fernandes
MRMaria Fernanda Setúbal Destro Rodrigues
Maria Fernanda Setúbal Destro Rodrigues
DGDouglas Magno Guimaraes
Douglas Magno Guimaraes
FNFabio Daumas Nunes
Fabio Daumas Nunes
KFKristianne Porta Santos Fernandes
Kristianne Porta Santos Fernandes